A hepatitis B vaccine trial involving newborns in Guinea-Bissau will not proceed after failing to secure government approval. The study was set to receive $1.6m from the CDC and $1.6m from private partners; the government now controls the researchers’ vaccines and plans a universal birth dose in 202